

**[Jeroen Luyten](#), Roselinde Kessels, Peter Goos
& Philippe Beutels**

Public preferences for prioritizing preventive and curative health care interventions: a discrete choice experiment

**Article (Accepted version)
(Refereed)**

Original citation:

Luyten, Jeroen, Kessels, Roselinde, Goos, Peter and Beutels, Philippe (2015) *Public preferences for prioritizing preventive and curative health care interventions: a discrete choice experiment*. [Value in Health](#), 18 (2). pp. 224-233. ISSN 1098-3015

DOI: [10.1016/j.jval.2014.12.007](https://doi.org/10.1016/j.jval.2014.12.007)

© 2015 [International Society for Pharmacoeconomics and Outcomes Research \(ISPOR\)](#)

This version available at: <http://eprints.lse.ac.uk/61270/>

Available in LSE Research Online: March 2015

LSE has developed LSE Research Online so that users may access research output of the School. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LSE Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. You may freely distribute the URL (<http://eprints.lse.ac.uk>) of the LSE Research Online website.

This document is the author's final accepted version of the journal article. There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

Public preferences for prioritizing preventive and curative health care interventions: a discrete choice experiment

Luyten Jeroen, Kessels Roselinde, Goos Peter & Beutels Philippe

Abstract [First-level Header]

Objective: Setting fair health care priorities counts among the most difficult ethical challenges our societies are facing. Through a discrete choice experiment we elicited the Belgian adult population's (18-75y; N = 750) preferences for prioritizing health care and we investigated whether these preferences are different for prevention versus cure.

Methods: We used a Bayesian D-efficient design with partial profiles, which enables considering a large number of attributes and interaction effects. We included the attributes 1) type of intervention (cure versus prevention); 2) effectiveness; 3) risk of adverse effects; 4) severity of illness; 5) link between the illness and patient's health-related lifestyle; 6) timespan between intervention and effect, and 7) patient's age group.

Results: All attributes were statistically significant contributors to the social value of a health care program, with patient's lifestyle and age being the most influential ones. Interaction effects were found, showing that prevention was preferred to cure for disease in young adults, as well as for severe and lethal disease in people of any age. However, substantial differences were found in the preferences of respondents from different age groups, with different lifestyles and different health states.

Conclusion: Our study suggests that, according to the Belgian public, contextual factors of health gains like patient's age and health-related lifestyle should be considered in priority setting decisions. The studies, however, also revealed substantial disagreement in opinion between different population subgroups.

Introduction [First-level Header]

One of the greatest challenges for the future consists in finding a fair match between ever-increasing medical needs and possibilities on the one hand, and finite health care budgets on the other. Consensus exists that such priority setting should reflect a concern for both efficiency (making maximal use of valuable resources) and equity (avoiding that some people become deprived of their deserved share) (1,2). Over the past decades, the concern for efficiency has been operationalized in cost-utility analysis (CUA), informing decision makers on the ratio between incremental costs and incremental Quality-Adjusted Life Years (QALYs) attributable to interventions (3). Equity, however, remains a much more elusive concept as a large number of contextual considerations of patients, illnesses or interventions could justify a more or less favorable weighing in rationing decisions (4). Therefore, an important research objective remains to clarify which distributive principles carry social support.

The aim of this paper is to contribute to the empirical literature describing the general public's distributive preferences regarding health care. We do so by means of a discrete choice experiment (DCE) held in a representative sample of the Belgian adult population. We pay specific attention to the following two issues. First, published studies about preferences for health care resource allocation largely ignored the difference in nature between prevention and cure. Unlike cure, however, prevention: 1) avoids the intangible costs of experiencing ill-health 2) can give rise to substantial externalities, with consequences for both efficiency and equity (5) (e.g. herd immunity through vaccination (6); 3) is closely related to social justice (e.g. by adjusting social determinants of health) (7); and 4) is only attributed a small fraction (< 5%) of the health care budget in most countries (8), and may be first to be cut in times of scarcity. In this study, we pay specific attention to the relative value of either type of health care and investigate whether their nature affects rationing principles. Second, an important criticism against studies eliciting social preferences is that aggregation covers up important heterogeneity in the ethical views of different respondents (7). We therefore pay much attention to differences in the preferences of relevant subgroups, via the inclusion of several respondent characteristics as covariates in our analysis.

Methods [First-level Header]

Discrete choice experiments (DCEs) are a widely used technique to quantify individuals' preferences by observing their stated choices in a number of hypothetical scenarios (9-11). Respondents are confronted with a sequence of choice sets consisting of two or more competing options. For each choice set they have to indicate the option they like best. The options are described in terms of a fixed set of attributes or dimensions that differ in their levels. The data from a DCE allow the assessment of the relative importance of each attribute in the total value attributed to the options under valuation.

DCEs are predominantly used to elicit personal preferences (for a general review of applications, see 12), but, in a number of studies, they have also been used to explore a population's social and ethical views regarding priority setting in health care (e.g. 13, 14; for specific reviews, see 15-17). One motivation for using DCEs in the latter context is that respondents are forced to consider the consequences of their choice (choosing for one option implies foregoing of the other), which avoids that they simply ignore the fact that health care resources are limited.

Conducting a DCE involves the following steps: 1) identification of the attributes and attribute levels; 2) experimental design of the choice sets; 3) survey development; 4) sample selection and survey administration; and 5) data analysis.

Identification of the attributes and attribute levels [Second-level Header]

For our research objective, it was important to identify a number of decontextualized, generic characteristics that provide a workable description of both preventive and curative interventions. These characteristics should enable respondents to make a meaningful judgment regarding the necessity to reimburse a given intervention. We considered literature review and expert opinion the preferable sources of information. Reviews have classified considerations, potentially relevant for rationing health care programmes, in three groups: characteristics belonging to the patient, the intervention and the health condition (15,18). We updated a review of DCEs about priority setting (17) and identified 12 DCEs exploring the social value of health care (13, 14, 17, 19-27). We reviewed these studies focusing on the attributes used. We observed that all studies used combinations of attributes to indicate what would happen when a patient would not receive care (severity of illness, expressed in morbidity and/or mortality), and what would happen in case a patient received care

(effectiveness of the intervention/health improvement). Additionally, the studies involved a cost or budget impact attribute, the number of patients affected, alternative treatment options and characteristics of the recipient (mainly age or health-related lifestyle).

The reviewed studies, however, mainly focused on cure, either explicitly or implicitly by shaping a context that is intuitively associated with curing patients, rather than with preventing illness. Therefore, we carried out a separate review of studies aiming to elicit preferences for prevention in order to find additional attributes. In a review of 114 DCEs (12), we found nine specifically applied to preventive interventions such as screening tests or vaccines (28-36) These nine studies suggested the inclusion of two additional attributes in our DCE, namely the intervention's risk on adverse effects and the timespan between the intervention and its clinical effect.

In sum, our literature review suggests the following list of nine attributes as most useful to include in our DCE: type of intervention (curative or preventive), effectiveness of the intervention, adverse effects associated with the intervention, severity of illness, cost of the intervention, number of patients, relation to health-related lifestyle, timespan between the intervention and the expected effect and age group of the patient.

Subsequently, we organized group discussions with convenience samples consisting of researchers (N = 10) and lay persons (N = 14) in which we presented interventions in terms of these nine characteristics to investigate whether we overlooked potentially important attributes and whether the descriptions we used for the attributes and their levels allowed a realistic mental image of a health care program. No additional attributes were considered essential. However, when we tested exploratory choice sets, it appeared that inclusion of all nine attributes made the cognitive burden too large for respondents. Respondents not only had to compare the characteristics of the intervention and the disease, but they also had to consider scale differences between both programs (cost and number of patients). This extra dimension required respondents to make calculations and made them raise questions for clarification. Therefore, we decided to exclude the attributes cost and number of patients by mentioning in every choice set that the interventions had the same cost and were beneficial for the same number of patients.

The next challenge was to refine the wording used to describe the attributes and their levels, and to consider other than verbal presentations of the attribute levels. First, we presented all attributes to our convenience sample in various formulations to determine which one was

easiest to understand. Since the use of attributes representing risks or chances is cognitively demanding, we considered using visualizations for the levels of the attributes effectiveness, risk on adverse effects and lifestyle instead of verbal descriptions (37). However, we learnt that a verbal description was most reliable, because it minimized the cognitive burden imposed on the respondents while still bringing across the intended meaning. Also for the other attributes, we experimented by describing levels using numbers and percentages, and found that the choice task was most intuitive when we described levels verbally. Terms such as ‘rarely’ and ‘often’ are more judgmental than numbers and chances (e.g. 1 adverse effect per 100 interventions) and they may translate into different numerical equivalents in different respondents. Using probabilities, however, does not guarantee equal interpretation (e.g. is a chance of 1 per 100 rare or often?). As for our purpose the qualitative rather than quantitative judgment of the respondent was what mattered, we opted for qualitative descriptions for a limited number of attribute levels.

We utilized three levels for each attribute, except for the attributes type of intervention, which has two levels, and age group of the patient, which has five levels. For the age attribute, we decided against covering all ages because this would make the age groups very wide. Instead we opted for equally wide age intervals at different stages of life. **Table 1** shows the descriptions of the attributes and their levels used. We presented the attributes one by one to the members of our convenience sample and asked them how they interpreted each attribute and attribute level. We encountered no difficulties in understanding.

Table 1: Attributes and levels.

Attribute	Level
What type of intervention is it?	<ol style="list-style-type: none"> 1. preventive (aiming to prevent healthy persons from becoming ill) 2. curative (aiming to cure people who are ill)
How big is the probability of success of the intervention?	<ol style="list-style-type: none"> 1. 1 in 3 is successful (33%) 2. 2 in 3 is successful (66%) 3. always successful (100%)
How often do adverse effects occur?	<ol style="list-style-type: none"> 1. often 2. rarely 3. never
How severe is the illness for which the intervention is developed?	<ol style="list-style-type: none"> 1. not lethal, but everyone who gets the disease will experience a short period of illness without lasting effects (not severe) 2. not lethal, but everyone who gets the disease will experience a severe and lasting reduction in quality of life (severe) 3. lethal, everyone who gets the disease will die from it (lethal)
Does the patient cause the disease through his or her own lifestyle?	<ol style="list-style-type: none"> 1. fully 2. partly 3. not at all

How long does it take before the patient becomes ill/ shows signs/symptoms of illness?	<ol style="list-style-type: none"> 1. after 20 years 2. after 5 years 3. within a year
At what age does the patient become ill?	<ol style="list-style-type: none"> 1. 80 – 90 years 2. 60 – 70 years 3. 40 – 50 years 4. 20 – 30 years 5. 0 – 10 years

Experimental design of the choice sets [Second-level Header]

The DCE presented respondents with 14 choice sets of two competing medical interventions, termed ‘profiles’ henceforth. The profiles are combinations of levels of the seven attributes in **Table 1**. To limit the cognitive burden imposed on the respondents, we used ‘partial profiles’ (38-40), i.e. we varied the levels of only four of the seven attributes in the choice sets and kept the levels of the other attributes constant. However, different attributes are held constant across choice sets at levels that change between choice sets. We did show the constant attributes to the respondents. This improves the validity of the parameter estimates on the one hand (41), and allows for the estimation of interaction effects on the other hand. To facilitate the choice tasks, we highlighted the varying attributes in each choice set. **Figure 1** shows an example choice set where respondents had to choose between two interventions A and B.

Figure 1: Example of a choice set.

Medical interventions A and B are exactly equally expensive and they apply to a similar number of patients. If you were forced to make a choice, which of the two interventions should be reimbursed by the government? To make it easier for you, we have highlighted in yellow (gray in this figure) the characteristics that differ between both interventions. There are no right or wrong answers; we are interested in your opinion.

	A	B
What type of intervention is it?	Curative (meant to cure patients who are ill)	Preventive (meant to prevent healthy persons from becoming ill)
How big is the probability of success of the intervention?	2 in 3 is successful	Always successful
How often do adverse effects occur?	Often	Often
How severe is the illness for which the intervention is developed?	Not lethal, but everyone who gets the disease will experience a severe and lasting reduction in quality of life	Lethal, everyone who gets the disease will die from it
Does the patient cause the disease through his or her own lifestyle?	Not at all	Not at all
How long does it take before the patient becomes ill/ shows signs/symptoms of illness?	Within a year	Within a year
At what age does the patient become ill?	0 to 10 years	40 to 50 years
YOUR PREFERENCE:	<input type="checkbox"/>	<input type="checkbox"/>

To maximize the information content of the DCE, we created three different surveys by constructing a partial profile design involving 42 choice sets and dividing it into three groups of 14 choice sets such that each group or survey has a similar partial profile design structure (see below). In constructing the design profiles, we excluded four unrealistic combinations of levels of two attributes [shown in **Appendix A in Supplemental Materials at: XXX** (which also includes the three surveys)]. We ensured that each survey was filled out an equal number of times. As pointed out by Sándor and Wedel (74), using 42 instead of 14 different choice sets results in a larger amount of information on the respondents' preferences and therefore in more precise estimates of the relative importance of the attributes and attribute levels.

Besides the estimation of the main effects of the attributes, we were also interested in estimating the interactions between 'type of intervention' and any other attribute. However, because of the disallowed level combinations associated with the attribute 'timespan' (shown in **Appendix A in Supplemental Materials at: XXX**), the interaction between 'type of intervention' and 'timespan' cannot be estimated. As a discrete choice model, we used a multinomial logit (MNL) model, which is common practice in discrete choice design and analysis (10). The partial profile design in **Appendix A (in Supplemental Materials at: XXX)** is D-efficient or D-optimal for the MNL model, meaning that it guarantees precise estimates of the main effects and the interactions between 'type of intervention' and five other attributes (43).

Each choice set of the D-efficient partial profile design varies the levels of four of the seven attributes. These varying attributes differ from choice set to choice set. We determined them using the attribute balance approach that attempts to vary each attribute in an equal number of choice sets and to pair varying attributes an equal number of times (39, 40). That is why each attribute is varied in eight choice sets of each survey of the partial profile design.

The D-efficient partial profile design takes into account prior knowledge concerning the respondents' preferences. For our DCE, for example, it generally holds that the expected priority ranking for reimbursement of interventions is, from low to high, related to a mild disease, followed by a severe, but not lethal disease, and finally, a lethal disease. Similarly, for all other attributes, we took into account expert prior information about the most logical ordering of the levels of the attributes, from low priority to high priority, the result of which is shown in **Table 1**. We also ranked the attributes in order of expected importance and expressed our uncertainty regarding the a priori orderings of the attributes and attribute levels

in a multivariate normal prior distribution. In **Appendix B (in Supplemental Materials at: XXX)**, we discuss in detail how we obtained that multivariate normal prior distribution to optimize the design. The design that maximizes the information content of the DCE [as measured by the log-determinant of the information matrix; see (43)], when averaged over that prior distribution, is called a Bayesian D-efficient design. The Bayesian D-efficient design approach is increasingly considered a state of the art approach for DCEs (see, e.g., 43-47, see also **Appendix C in Supplemental Materials at: XXX**). Major benefits of Bayesian D-efficient designs are that, using a proper prior distribution, they avoid choice sets in which one profile is completely dominating the other profile(s) on every attribute (48), and (as demonstrated below) such designs can be constructed to efficiently estimate interaction effects.

Survey development [Second-level Header]

We provided respondents with a web link that allowed them to carry out the choice tasks at their earliest convenience. To help respondents, we presented a thorough explanation of the choice tasks at the beginning of the DCE to familiarize them with 1) the context of increasing scarcity in health care, the problem of setting fair priorities and our objective to investigate how the general population thinks about this difficult ethical policy issue, and 2) all seven attributes and their levels and how they are used in the description of a treatment or a preventive intervention. We asked respondents to choose between two interventions of which only one could be reimbursed by the government.

After the DCE, we asked respondents a number of background questions concerning their age, gender, height, weight, educational attainment, family size, experience as health care worker (HCW), smoking status and experience with severe illness (personal or within the family). In order to have an estimate of the respondent's current health state, the respondents also had to complete the EuroQol health survey (i.e. the Visual Analogue Scale (VAS) and the generic EQ-5D-5L) (49, 50). These are all variables that we a priori considered to be of potential relevance to someone's health care preferences.

Sample selection and survey administration [Second-level Header]

In June 2012 a sample was drawn, representative of the Belgian population in terms of age, gender, region and educational attainment, from an actively managed, continuously updated panel of 10,753 Belgians. Participation was incentivized with credits by means of which, after

a number of positively evaluated survey participations, gifts could be bought and a lottery organized on a per survey basis. Only one respondent per household was allowed. The market research company guarantees high-quality data through checks and ensures that only ‘serious’ respondents are included. To this end, fraudulent, inattentive, hyperactive or conditioned respondents were removed from the sample, e.g. respondents who complete the survey unreasonably fast (‘speedsters’), consistently give the same answer (‘straightliners’), etc.

A total of 30% (N = 3,160) of the 10,753 contacted individuals agreed to participate, of which 937 were selected based on the quota requirements. Of the selected individuals, 149 did not finish the survey and 38 did not meet the quality criteria. This left us with a sample of 750 respondents (250 respondents for each of the three versions of the survey), and 10,500 observed choices in total, i.e. 14 per respondent. Respondents were distributed proportionally over the three survey versions according to language, gender and age. **Table 2** compares basic characteristics of the sample to those of the population, showing overall good agreement. Given the societal context of this study, and a lack of clarity about the criteria (additional to the ones described in the previous paragraph) that can identify irrational response data in a DCE without imposing preferences (51, 52), all 750 respondents were included in our analysis.

Table 2: Sample characteristics relative to those of the Belgian population.

	Sample	Belgian population
Language		
Dutch	56%	56%
French	44%	44%
Gender		
Male (M)	50%	50%
Female (F)	50%	50%
Gender per age group †		
18 – 25 M	6%	6%
18 – 25 F	6%	6%
25 – 34 M	9%	9%
25 – 34 F	10%	9%
35 – 44 M	10%	11%
35 – 44 F	10%	10%
45 – 54 M	10%	10%
45 – 54 F	11%	10%
55 – 64 M	9%	8%
55 – 64 F	10%	8%
65 – 74 M	6%	6%
65 – 74 F	4%	6%
Level of education *		
None or lower education	8%	19%
Lower secondary	10%	20%
Higher secondary	31%	33%
Higher non-university	35%	18%
University	15%	10%

Province		
Antwerp	15%	16%
West Flanders	10%	11%
East Flanders	13%	13%
Limburg	8%	8%
Hainault	13%	12%
Liege	10%	10%
Luxemburg	3%	2%
Namur	5%	4%
Brussels	10%	10%
Flemish Brabant	11%	10%
Walloon Brabant	3%	3%
Smoking status ‡		
Never smoked	45%	54%
Ex-smoker	30%	22%
Smoker	25%	25%

Source Belgian Data: Federale Overheidsdienst Economie (70)

† Age: The percentages reported are proportions in the selected population (18-75), representing 71% of the total Belgian population.

* Education: The percentages reported for the Belgian population are for the age group 15 years or older. The percentages for our sample are only for the age group 18-75 years. The overrepresentation of higher educated respondents in our sample as compared to the total population can be explained by our exclusion of the group 15-18 years that is too young for higher education, and the age group 75 years or older for which higher education was less democratically accessible.

‡ Smoking percentages from the population are based upon the following study (71) and are representative for the population aged 15 years or older.

2.5 Data analysis [Second-level Header]

The data we collected through our DCE allow quantification of and statistical inference about the relative importance of the attributes and attribute levels in assessing the priority ranking of a health intervention. This is done by estimating the respondents' utility function as part of the multinomial logit (MNL) model, using a maximum likelihood approach. The utility function is represented by the sum of the utilities of the attributes' main and interaction effects under study. The overall significance of the attributes was computed using likelihood ratio (LR) tests and the relative importance of the attributes was measured by $-\log$ (p-value of the LR test). We started our analysis by estimating the *a priori* MNL model, i.e. the model that seemed most useful when planning the entire study and which was used as a basis for constructing the D-efficient design for the DCE. That model includes the main effects of all attributes and the interactions between type of intervention and five other attributes. Next, we dropped the insignificant model terms until we obtained a final model in which all remaining effects had significant explanatory value. Preference heterogeneity (section 3.2) was assessed - in a separate analysis - by adding an interaction term in the model with a variable that we a


priori determined to be of potential interest (e.g. gender or respondent's age). We carried out the entire data analysis using the Choice Modeling platform in the statistical software package JMP 10.

Results [First-level Header]

Main and interaction effects [Second-level Header]

Figure 2 and **Table 3** summarize the results of our analysis. All 7 attributes are statistically significant contributors to the social value of a health care intervention, meaning that none of them is considered irrelevant to priority setting. As shown in **Figure 2**, the most influential attributes (based on the LR test) are the patient's health-related lifestyle and age. They are about twice as important as the intervention's effectiveness and about four times as important as severity of illness. Type of intervention is also an important attribute for the model because it appears in two significant interaction effects: between 'type of intervention' and 'patient's age' and between 'type of intervention' and 'severity of illness' (see below). Its importance is shown by the LR test for the joint significance of the three effects involving this attribute (LR Chi-square = 26.19; DF = 7; p-value = 0.0005). Timespan is the attribute that is least important.

Figure 2: Importance of the 7 attributes (main and interaction effects) to the social value of a health care program relative to the most important attribute 'lifestyle of patient', the importance of which is set to 100.



The main-effect estimates in **Table 3** represent the utilities attached to the different levels of the attributes. The direction of the coefficients across the levels of each attribute is in line with our *a priori* expectations. The attractiveness for reimbursement increased as the intervention was more effective or had a lower risk of adverse effects, when the disease was more severe or occurred earlier in time and when the patient's age and the link between the disease and the patient's lifestyle was lower. **Figure 4** visualizes this for the two most influential attributes: patient's age and link with patient's lifestyle (for the total sample and for specific subgroups, see section 3.2). Looking at the 95% confidence intervals for the utility estimates of each level we judge that most coefficients are different on a statistically significant level. In a few cases the level estimates did not significantly differ: the adverse effects levels 'never' and 'rarely', the patient's age levels '0-10 years' and '20-30 years' and the timing levels 'within a year' and 'after 5 years'.

Table 3: Estimates of coefficients in the MNL model, their 95% confidence intervals (CIs) and overall significances of the attributes using p-values obtained from likelihood ratio tests.


Term	Estimate	95% CI	P-value
Lifestyle of Patient			
fully	-0.3742	-0.4324; -0.3163	<0.0001
partly	0.0483	0.0046; 0.0921	
not at all	0.3259*	0.2685; 0.3833	
Age of Patient			
80 – 90 years	-0.6160	-0.7088; -0.5241	<0.0001
60 – 70 years	-0.0067	-0.0829; 0.0695	
40 – 50 years	0.1168	0.0479; 0.1857	
20 – 30 years	0.2206	0.1485; 0.2929	
0 – 10 years	0.2853*	0.2012 ; 0.3694	
Effectiveness			
33%	-0.2584	-0.3171; -0.2001	<0.0001
66%	0.0282	-0.0177; 0.0741	
100%	0.2302*	0.1765; 0.2840	
Severity of Illness			
not severe	-0.2210	-0.2946; -0.1476	<0.0001
severe	0.0653	0.0245; 0.1061	
lethal	0.1557*	0.0812; 0.2303	
Adverse Effects			
often	-0.1582	-0.2131; -0.1037	<0.0001
rarely	0.0856	0.0426; 0.1287	
never	0.0726*	0.0235; 0.1221	
Type*Age of Patient			
preventive*80 – 90 years	0.0120	-0.0397; 0.0638	0.0005
preventive*60 – 70 years	-0.0676	-0.1190; -0.0162	
preventive*40 – 50 years	-0.0480	-0.1038; 0.0078	
preventive*20 – 30 years	0.1103	0.0537; 0.1669	
preventive*0 – 10 years	-0.0067*	-0.0732; 0.0600	
curative*80 – 90 years	-0.0120*	-0.0638; 0.0397	
curative*60 – 70 years	0.0676*	0.0162; 0.1190	
curative*40 – 50 years	0.0480*	-0.0078; 0.1038	
curative*20 – 30 years	-0.1103*	-0.1669; -0.0537	
curative*0 – 10 years	0.0067*	-0.0600; 0.0732	
Timespan			
after 20 years	-0.0843	-0.1529; -0.0155	0.0404
after 5 years	0.0234	-0.0273; 0.0741	
within a year	0.0609*	0.0069; 0.1148	
Type*Severity of Illness			
preventive*not severe	-0.0431	-0.0801; -0.0059	0.0487
preventive*severe	0.0345	-0.0041; 0.0731	
preventive*lethal	0.0086*	-0.0330; 0.0503	
curative*not severe	0.0431*	0.0059; 0.0801	
curative*severe	-0.0345*	-0.0731; 0.0041	
curative*lethal	-0.0086*	-0.0503; 0.0330	
Type			
preventive	0.0137	-0.0297; 0.0571	0.5376
curative	-0.0137*	-0.0571; 0.0297	

*Coefficient estimates corresponding to the last level of an attribute, either as main effect or involved in an interaction, are indicated in italic to stress that they are calculated as minus the sum of the estimates for the other levels of that attribute. To illustrate, the value of 0.0086 for the interaction effect *Type[preventive]*Severity of illness[lethal]* is obtained as $-(-0.0431+0.0345)$.


In **Figure 3** the two interactions involving type of intervention are plotted. Our data suggest that the relative value of cure versus prevention differed as a function of the age group of the patient and the severity of the health problem. As shown in **Panel A**, however, the interaction with age is mainly due to the upward kink at 20-30 years in the value of prevention and the downward kink at the same age category in cure. For patients older than 30, the utility of prevention declined, whereas the value of cure remained relatively stable over the age interval from 20 to 70. However, we judge that this difference in utility between prevention and cure in older age groups is statistically not significant, since from the 95% confidence intervals we observe that the interaction effects *type[preventive]*age of patient[40-50 years]* and *type[preventive]*age of patient[60-70 years]* belong to each other's confidence interval. Regarding the second interaction, **Figure 3's Panel B** shows that severity of illness had a larger impact on the utility of a preventive intervention than on that of a curative one. Prevention was valued less than cure in case of a non-severe, transient illness. However, it was valued more for severe long-lasting and life-threatening diseases. Our respondents did not consider effectiveness, risk of adverse effects or lifestyle to be of differential importance in choosing between prevention and cure (i.e. these attributes did not interact with type of intervention).

Figure 3: Marginal utility values for different combinations of “Age of Patient” and “Type of Intervention” (Panel A) and for different combinations of “Severity of Illness” and “Type of Intervention” (Panel B).

A.



B.



Preference heterogeneity [Second-level Header]

We found many differences in the preferences of various subgroups (indicated by a statistically significant interaction effect). The largest interactions (based on the LR test) were found between respondent's age and patient's age, and between respondent's smoking status and patient's lifestyle.

Respondent's age [Third-level Header]

Younger respondents attributed significantly more importance to patient's age ($p < 0.001$), severity of illness ($p < 0.001$) and patient's lifestyle ($p = 0.0001$). To visualize the impact of the respondent's age, we partitioned the respondents of our dataset in three age groups: 18-35y, 36-60y and 61-75y (see **Fig. 4**). For the youngest respondents, the social value of an intervention depended more strongly on the patient's age (**Panel A**, dotted line) and the link between the disease and the patient's lifestyle (**Panel B**, dotted line) than for the older respondents.

Gender [Third-level Header]

The covariate gender appeared in two significant interactions, one involving the attribute patient's age ($p = 0.003$) and one involving the attribute effectiveness ($p = 0.01$). Female respondents attached less value to interventions for older patients than male respondents. Male respondents attributed a higher value to effectiveness.

Level of education and experience in health care [Third-level Header]

Respondents with a degree of higher education (university or non-university) were more willing to ration based on age ($p < 0.001$), and attribute more importance to severity of illness ($p < 0.0001$). In addition they attributed more value to prevention ($p = 0.02$). No differences in opinion were found between higher and lower educated respondents for the attributes lifestyle, effectiveness and adverse effects. Present or past experience as health care worker (14% of the sample) did not result in significant interactions.

Household [Third-level Header]

The larger the household of the respondent, the more prevention was preferred to cure ($p = 0.003$) and the more the value of health care decreased as a function of patient's age ($p =$

0.002). Respondents living with children gave more importance to patient's age. No significant interactions were found with other attributes.

Health state [Third-level Header]


We found significant interactions with the respondent's VAS and EQ-5D-5L scores. The lower the VAS score, the lower the importance of the patient's age group ($p < 0.0001$) and the stronger the preference for cure over prevention ($p < 0.008$). The lower their EQ-5D-5L score, the more likely respondents were to prefer cure over prevention ($p < 0.006$) and to prefer current health gains over future ones ($p < 0.01$). Respondents who reported having had personal experience with severe illness attached greater value to cure than to prevention ($p < 0.002$), and to current rather than to future health gains ($p < 0.01$). They attributed less importance to adverse effects ($p < 0.04$) and are less inclined to take the age of patients into account ($p < 0.006$). We also partitioned our sample in a 'good health' group (74% of the sample) and a group with 'present or past health problems' (26%), depending on whether or not they had personal experience with severe illness, or had an EQ-5D-5L score below 0.6 or a VAS score below 60. Both groups differ in that the 'good health' group preferred prevention ($p < 0.002$), discounted future health gains to a lesser extent ($p = 0.04$) and was more willing to ration based on age ($p = 0.01$). Respondents' choices did not differ significantly based on experience with severe illness in their family.

Lifestyle [Third-level Header]

Whether or not the respondent is a smoker is a highly influential covariate and, hence, an important factor explaining preference heterogeneity among the respondents. Smokers clearly attributed a lower importance to the attributes lifestyle ($p < 0.0001$) and patient's age ($p = 0.0008$), preferred cure to prevention ($p < 0.0001$), and discounted future health gains to a greater extent ($p = 0.04$). Also, Body Mass Index (BMI) turns out to be an important covariate. The higher the BMI score, the less a respondent takes into account the patient's age ($p < 0.0032$), severity of illness ($p = 0.0006$) and the disease's link with lifestyle ($p = 0.04$) and the more (s)he prefers cure to prevention ($p = 0.0034$) and discounts future health gains ($p = 0.008$). To visualize the differential valuation by respondents with a 'healthy' lifestyle and patients with an 'unhealthy' lifestyle, we partitioned the respondents in two groups, one group (in total 38% of the sample) containing respondents with a BMI exceeding 30 [i.e. the obesity threshold (53)] as well as smokers and one group containing non-smokers that have a BMI lower than 30. The 'unhealthy' lifestyle group preferred cure to prevention ($p < 0.0001$),

attributed a lower weight to lifestyle ($p < 0.0001$) and patient's age ($p < 0.0001$) (as illustrated in **Fig. 4's Panel B**), and, remarkably, attached more importance to the risk of adverse effects ($p = 0.02$).

Figure 4: Marginal utility values for the attributes “Age of Patient” (Panel A) and “Lifestyle of Patient” (Panel B) for the entire sample (general population) and for different respondent subgroups [respondents aged 18-35 years, aged 60-75 years and a group defined as having an ‘unhealthy’ lifestyle (i.e. being smoker or obese)].



Discussion [First-level Header]

The objective of our study was to investigate on which basis the Belgian population wants to set health care priorities. Although characteristics of the intervention (effectiveness and risk of adverse effects) and of the illness (severity of illness and timespan) were found to matter, it was mainly the characteristics of the recipient that drove respondents' preferences. Priority was given to younger patients and to those who have not somehow caused their own illness. We also detected substantial heterogeneity in the preferences: young, healthy, highly educated or more health-conscious adults responded in a markedly different way than older, unhealthy, less well educated and health-unconscious ones.

Our results confirm studies in other countries indicating that the context shapes the social value of QALYs, and that the general public's distributive preferences diverge from a simple health maximization approach, as would be prescribed by CUA (i.e. minimizing cost/QALY) (e.g. 13, 14, 16, 17, 19, 20, 54; 24, 25, ; for reviews see 15, 16 or 55). Many of these studies also observe a public preference for prioritizing younger patients over older ones and several ones describe how a substantial number of participants want to account for self-inflicted illness. However, our results seem to diverge from these other studies in the strong impact of the lifestyle attribute, and the relatively limited impact of severity of illness to priority setting.

We paid specific attention to the difference between prevention and cure. A few studies in the literature also compared stated preferences for both types of health care (24, 56-60, 69). These studies found no preference (56, 57), a preference for prevention (24, 59-60) or a preference for cure (58, 69). Our sample valued prevention higher than cure only when it is targeted at relatively young age groups and when it protects against more severe illness. However, as the self-inflicted nature of a health condition was a factor of major relevance in our study, indirectly, our results can also be interpreted as providing further support for prevention in general. An allocation scheme that accounts for individual responsibility would mainly ration on curative treatments as accountability for lifestyle is less relevant for (not) providing prevention, especially when it comes to primary prevention. Preventive programs can incentivize, or even *enable* citizens to adopt healthy and responsible lifestyles before their lifestyle-associated risk-exposure requires cure. Currently, preventive “lifestyle” policies such as alcohol, fat, sugar or smoking taxes are gaining interest (61, 62). Such measures, if effective, would increase short-term government income and reduce lifestyle-related morbidity.

Some limitations of our study must be mentioned. First and foremost, priority setting in health care requires societal support (63). But the majority is not necessarily right (64, 65). We observed that the support for age-based rationing and accounting for lifestyle depends on the age and lifestyle of the respondents themselves, indicating some degree of self-serving answers. Whereas we conveyed to respondents to answer as citizens (a societal view) and not as potential health care consumers (an individual view), and whereas self-serving answers are not necessarily unjust, this does raise suspicion of partiality. How this can be avoided, and how we can construct a more effective ‘veil of ignorance’ in social preference studies, remains a challenge for further research. But even with impartial answers, age-based rationing and accounting for lifestyle remain controversial grounds for setting priorities (for an elaborate discussion, see 66). The results of public opinion research in this area should always be complemented by ethical considerations. Therefore, instead of being directly useful to priority-setting decisions, our survey in the first place supports the need for a more extensive public debate about the appropriate role of age and lifestyle in health care rationing.

Second, although our sample was broadly representative of the Belgian population, respondents were recruited from an online panel. This excluded respondents older than 75 years and membership of the panel may be associated with unobservable characteristics.

Third, we surveyed our sample on a complex topic, in a single recording. We encouraged respondents to think thoroughly about their answer and evidence suggests that respondents' answers to DCEs like ours are reliable (21). Nonetheless, it would be interesting to repeat this study in a non-panel sample (e.g. generated through random digit dialing of telephone numbers), and to organize a follow-up study in the same sample to compare the results. Fourth, an inherent limitation of DCEs is that only a limited number of attributes can be used. Although we included a relatively large number of attributes, the choice alternatives we presented remain simplified versions of real health care programs. Fifth, because this simplified the choice tasks, we excluded the cost attribute. A disadvantage of this was that it became impossible to quantify willingness to pay for changes in the attributes levels. Such inferences, however, were not our primary objective, and, moreover, they have also been shown to be less informative than expected on some occasions (67, 68).

References [First-level Header]

1. Wagstaff A. QALYs and the equity-efficiency trade-off. *J Health Econ* 1991;10;21-41.
2. Sen A. Why health equity? *Health Econ* 2002;11;659-66.
3. Gold E, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. Oxford University Press: Oxford; 1996.
4. McIntyre D, Mooney G. The Economics of Health Equity. Cambridge University Press: New York; 2007.
5. Carande-Kulis V, Getzen TE, Thacker SB. Public goods and externalities: a research agenda for public health economics. *J Public Health Manag Pract*. 2007, 13(2):227-32.
6. Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. *Expert Review of Vaccines* 2003;2; 649-60.
7. Powers M, Faden RR. Social Justice: The Moral Foundations of Public Health and Health Policy. Oxford University Press: Oxford; 2008.
8. OECD. Health expenditure and financing. 2010. Available at: <http://www.oecd.org/health/health-systems/oecdhealthdata.htm>. [Accessed Month day, year] (Accessed May 1, 2013).
9. Louviere J, Hensher D, Swait J. Stated Choice Methods: Analysis and Applications. Cambridge University Press: Cambridge; 2000.
10. Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Springer: Dordrecht; 2008.
11. Bridges JFP, Hauber AB, Marshall D, et al. Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. *Value Health* 2011;14; 403-13.
12. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. *Health Econ* 2012;21;145-72.
13. Lancsar E, Wildman J, Donaldson C, et al. Deriving distributional weights for QALYs through discrete choice experiments. *J Health Econ* 2011;30;466-78.
14. Norman R, Hall J, Street D, Viney R. Efficiency and equity: A stated preference approach. *Health Econ* 2012;volume:page-range 22;568-81
15. Schwappach DL. Resource allocation, social values and the QALY: a review of the debate and empirical evidence. *Health Expect* 2002b;5; 210-22.
16. Dolan P, Shaw R, Tsuchiya A, Williams A. QALY maximisation and people's preferences: a methodological review of the literature. *Health Econ* 2005;14;197-208.
17. Green C, Gerard K. Exploring the social value of health-care interventions: A stated preference discrete choice experiment. *Health Econ* 2009;18;951-76.
18. Olsen JA, Richardson J, Dolan P, Menzel P. The moral relevance of personal characteristics in setting health care priorities. *Soc Sci Med* 2003;57;1163-72.
19. Bryan S, Roberts T, Heginbotham C, McCallum A. QALY-maximisation and public preferences: results from a general population survey. *Health Econ* 2002;11; 679-93.
20. Schwappach DL. Does it matter who you are or what you gain? An experimental study of preferences for resource allocation. *Health Econ* 2003;12; 255-67.
21. Schwappach DL, Strasmann TJ. "Quick and dirty numbers"? The reliability of a stated-preference technique for the measurement of preferences for resource allocation. *J Health Econ* 2006;25;432-48.
22. Baltussen R, Stolk E, Chisholm D, Aikins M. Towards a multi-criteria approach for priority setting: an application to Ghana. *Health Econ* 2006;15; 689-96.
23. Tappenden P, Brazier J, Ratcliffe J, Chilcott J. A stated preference binary choice experiment to explore NICE decision making. *Pharmacoeconomics* 2007;25;685-93.
24. Mortimer D, Segal L. Is the value of a life or life-year saved context specific? Further evidence from a discrete choice experiment. *Cost Eff Resour Alloc* 2008;6; 8.
25. Ratcliffe J, Bekker HL, Dolan P, Edlin R. Examining the attitudes and preferences of health care decision-makers in relation to access, equity and cost-effectiveness: a discrete choice experiment. *Health Policy* 2009;90;45-57.
26. Mentzakis E, Stefanowska P, Hurley J. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. *Health Econ Policy Law* 2011;6; 405-33.
27. Defechereux T, Paolucci F, Mirelman A, et al. Health care priority setting in Norway a multicriteria decision analysis. *BMC Health Serv Res* 2012;12; 39.
28. Ryan M, Hughes J. Using conjoint analysis to assess women's preferences for miscarriage management. *Health Econ* 1997;6;261-73.
29. Hall J, Kenny P, King M, et al. Using stated preference discrete choice modelling to evaluate the introduction of varicella vaccination. *Health Econ* 2002;11;457-65.

30. Salkeld G, Solomon M, Short L, et al. Evidence-based consumer choice: a case study in colorectal cancer screening. *Aust N Z J Public Health* 2003;27;449-55.
31. Bishop AJ, Marteau TM, Armstrong D, et al. Women and health care professionals' preferences for Down's Syndrome screening tests: a conjoint analysis study. *BJOG* 2004;111; 775-9.
32. Ryan M, Diack J, Watson V, Smith N. Rapid prenatal diagnostic testing for Down syndrome only or longer wait for full karyotype: the views of pregnant women. *Prenat Diagn* 2005;25; 1206-11.
33. Wordsworth S, Ryan M, Skatun D, Waugh N. Women's preferences for cervical cancer screening: a study using a discrete choice experiment. *Int J Technol Assess Health Care* 2006;22; 344-50.
34. Hall J, Fiebig DG, King MT, et al. What influences participation in genetic carrier testing? Results from a discrete choice experiment. *J Health Econ* 2006;25; 520-37.
35. Bishai D, Brice R, Girod I, et al. Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccine. *Pharmacoeconomics* 2007;25;143-54.
36. Lancsar EJ, Hall JP, King M, et al. Using discrete choice experiments to investigate subject preferences for preventive asthma medication. *Respirology* 2007;12;127-36.
37. Ancker JS, Senathirajah Y, Kukafka R, Starren JB. Design features of graphs in health risk communication: a systematic review. *J Am Med Inform Assoc* 2006;13; 608-18.
38. Green P. On the design of choice experiments involving multifactor alternatives. *J Consum Res* 1974;1; 61-8.
39. Kessels R, Jones B, Goos P. Bayesian optimal designs for discrete choice experiments with partial profiles. *J Choice Modelling* 2011;4; 52-74.
40. Kessels R., Jones B., and Goos P. (2014), An improved two-stage variance balance approach for constructing partial profile designs for discrete choice experiments, *Appl. Stochastic Models Bus. Ind.*, doi: [10.1002/asmb.2065](https://doi.org/10.1002/asmb.2065)
41. Dellaert BGC, Donkers B, van Soest A. Complexity effects in choice experiment-based models. *J Marketing Res* 2012;49; 424-34.
42. Sándor Z, Wedel M. Profile construction in experimental choice designs for mixed logit models. *Marketing Science* 2002;21;455-75.
43. Kessels R, Jones B, Goos P, Vandebroek M. The usefulness of Bayesian optimal designs for discrete choice experiments. *Appl Stoch Model Bus* 2011;27;173-88.
44. Kessels R, Goos P, Vandebroek M. A comparison of criteria to design efficient choice experiments. *J Marketing Res* 2006;43;409-19.
45. Kessels R, Jones B, Goos P, Vandebroek M. Recommendations on the use of Bayesian optimal designs for choice experiments. *Quality and Reliability Engineering International* 2008;24;737-44.
46. Rose JM, Bliemer MCJ. Constructing efficient stated choice experimental designs. *Transport Rev* 2009;29; 587-617.
47. Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. *Value Health* 2013;16; 3-13.
48. Crabbe M, Vandebroek M. Using appropriate prior information to eliminate choice sets with a dominant alternative from D-efficient designs. *Journal of Choice Modelling* 2012;5; 22-45.
49. Euroqol-group. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:page-range, p.199-208.
50. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20;1727-36.
51. Lancsar E, Louviere J. Deleting 'irrational' responses from discrete choice experiments: a case of investigating or imposing preferences? *Health Econ* 2006;15; 797-811.
52. Ryan M, Watson V, Entwistle V. Rationalising the 'irrational': a think aloud study of discrete choice experiment responses. *Health Econ* 2009;18;321-36.
53. Aasheim ET, Sovik TT. Global trends in body-mass index. *Lancet* 2011;377;1916-7; author reply 1917-18.
54. Dolan P, Cookson R. A qualitative study of the extent to which health gain matters when choosing between groups of patients. *Health Policy* 2000;51;19-30.
55. Shah K. Severity of illness and priority setting in healthcare: a review of the literature. *Health Policy* 2009;93;77-84.
56. Ubel PA, Spranca MD, Dekay ML, et al. Public preferences for prevention versus cure: what if an ounce of prevention is worth only an ounce of cure? *Med Decis Making* 1998;18;141-8.
57. Corso P. Prevention just in case or treatment just because: measuring societal preferences. *Harvard Health Policy Rev* 2006;7;32-41.
58. Schwappach DL. The equivalence of numbers: the social value of avoiding health decline: an experimental Web-based study. *BMC Med Inform Decis Mak* 2002a;2; 3.

59. Bosworth R, Cameron TA, DeShazo JR. Is an ounce of prevention worth a pound of cure? Comparing demand for public prevention and treatment policies. *Medical decision making: an international journal of the Society for Med Decis Mak* 2010;30; E40-56.
60. Johannesson M, Johansson PO. A note on prevention versus cure. *Health Pol* 1997;41;181-7.
61. Dharmasena S, Capps O, Jr. Intended and unintended consequences of a proposed national tax on sugar-sweetened beverages to combat the U.S. obesity problem. *Health Econ* 2012;21; 669-94.
62. Cook PJ, Durrance CP. The virtuous tax: lifesaving and crime-prevention effects of the 1991 federal alcohol-tax increase. *J Health Econ* 2013;32; 261-7.
63. Claxton K, Culyer AJ. Not a NICE fallacy: a reply to Dr Quigley. *J Med Ethics* 2008;34;598-601.
64. Richardson J. The poverty of ethical analyses in economics and the unwarranted disregard of evidence. In: Murray C ea, Summary measures of population health. World Health Organisation; 1997.
65. Hausman DM. Polling and public policy. *Kennedy Inst Ethics J* 2004;14; 241-7.
66. Denier Y, Gastmans C, Vandevelde A. Justice, luck and responsibility in health care: philosophical background and ethical implications for end-of-life care. Springer: Dordrecht; 2013.
67. Slothuus Skjoldborg U, Gyrd-Hansen D. Conjoint analysis. The cost variable: an Achilles' heel? *Health Econ* 2003;12;479-91.
68. Johnson FR, Mohamed AF, Ozdemir S, et al. How does cost matter in health-care discrete-choice experiments? *Health Econ* 2011;20; 323-30.
69. Corso PS, Hammitt JK, Graham JD, et al. Assessing preferences for prevention versus treatment using willingness to pay. *Medical Decis Making* 2002;22(Suppl.); S92-101.
70. FOD-economie. 2012. Belgische bevolking: feiten en cijfers. FOD-economie; 2012. Available at: http://statbel.fgov.be/nl/modules/publications/statistiques/bevolking/cijfers_bevolking_1_1_2009.jsp. [Accessed Month day, year] (Accessed May 1, 2013).
71. SIPH. 2008. Scientific Institute of Public Health: Health Survey Belgium 2008. Available at: http://www.vvsg.be/sociaal_beleid/gezondheidsbeleid/Documents/SamenvattingGezondheidstoestand.pdf. [Accessed May, 1, 2013].
72. Huber J, Zwerina K. The importance of utility balance in efficient choice designs. *J Marketing Res* 1996;33;307-17.
73. Carlsson F, Martinsson P. Design techniques for stated preference methods in health economics. *Health Econ* 2003;12; 281-94.
74. Sándor Z, Wedel M. Heterogeneous conjoint choice designs. *J Marketing Res* 2005;42;210-18.